Amgen Expands Oncology Pipeline With New Phase 1 AMG 436 Study in MSI-H/dMMR Tumors

Amgen Inc (AMGN) announced an update on their ongoing clinical study.

The Phase 1/1b study “A Phase 1/1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 436 as Monotherapy and in Combination With Other Therapies in Participants With Microsatellite Instability-high (MSI-H)/Mismatch Repair Deficient (dMMR) Solid Tumors” aims to test Amgen’s new cancer drug in hard-to-treat tumors. The trial focuses on early safety, dose finding, and how the drug moves through the body, which are key steps before larger studies and any revenue impact.

The main treatment is AMG 436, an experimental cancer drug given as a pill or infusion-style therapy depending on the final regimen. It is designed for people with advanced MSI-H or dMMR solid tumors, where standard options are limited and better targeted treatments could command premium pricing if successful.

The trial is interventional and non-randomized, meaning everyone knowingly receives active treatment rather than placebo. Participants move through parts in sequence, first with AMG 436 alone and then in combinations, and there is no blinding, so both doctors and patients know which treatment is given, keeping the focus on safety and dose rather than comparison.

The study uses several parts: initial dose escalation with AMG 436 alone, a food-effect substudy in the U.S., combination dose escalation, and later dose expansion stages including chemotherapy combos. This stepwise design lets Amgen fine-tune dosing and combinations before committing to larger, costlier Phase 2 or 3 trials that investors usually watch more closely.

Key timing markers matter for investors even at this early stage. The study was first submitted on 5 Feb 2026, signaling formal launch, and the latest update on 17 Mar 2026 confirms the design and recruiting status, while future primary and final completion dates will guide when safety and early activity data might start to appear.

Because the trial is still in Phase 1/1b, near-term earnings impact is limited, but a broad program in MSI-H/dMMR tumors could support the long-term oncology story for Amgen (AMGN). Positive safety and dose data would strengthen investor confidence in Amgen’s pipeline versus peers in precision oncology, while setbacks could shift attention toward larger, later-stage assets.

In the competitive context, several large pharma players already market drugs targeting MSI-H or dMMR cancers, so AMG 436 will likely need either better tolerability or strong combo data to stand out. Early updates that show clean safety and a clear recommended dose could support sentiment that Amgen can still carve out share in a crowded immuno-oncology space.

The market will likely treat interim news as a sentiment driver rather than a core valuation change until proof-of-concept data emerges. For now, the active and recently updated study underlines Amgen’s continued push in oncology, and the trial remains ongoing with full details available on the ClinicalTrials portal.

To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.